Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$0.36 -5.4%	$0.35	$0.22 ▼ $15.80	$18.87M	0.79	4.98 million shs	459,888 shs
CLYM Climb Bio	$1.45 +3.6%	$1.32	$1.05 ▼ $8.79	$94.61M	-0.11	204,297 shs	145,674 shs
IMUX Immunic	$0.93 -0.9%	$0.83	$0.56 ▼ $2.11	$90.08M	1.38	1.07 million shs	668,229 shs
IVVD Invivyd	$0.73 +5.5%	$0.79	$0.35 ▼ $2.74	$83.25M	0.52	639,784 shs	822,841 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	-5.43%	-27.88%	+26.37%	+36,039,900.00%	+36,039,900.00%
CLYM Climb Bio	+3.57%	0.00%	+15.08%	+14.17%	+144,999,900.00%
IMUX Immunic	-0.91%	-16.83%	+30.65%	-19.00%	-34.86%
IVVD Invivyd	+5.52%	-6.71%	+1.29%	+16.53%	-41.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	2.3435 of 5 stars	3.6	0.0	0.0	0.0	0.0	2.5	1.3
IMUX Immunic	2.9891 of 5 stars	3.6	2.0	0.0	0.0	3.3	2.5	0.6
IVVD Invivyd	2.9963 of 5 stars	3.6	4.0	0.0	0.0	0.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	0.00	N/A	N/A	N/A
CLYM Climb Bio	3.25	Buy	$9.00	520.69% Upside
IMUX Immunic	3.29	Buy	$7.50	705.15% Upside
IVVD Invivyd	3.25	Buy	$5.85	698.85% Upside

Current Analyst Ratings Breakdown

Latest ASBP, IMUX, CLYM, and IVVD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$7.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	($2.17) per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A
IVVD Invivyd	$36.69M	2.39	N/A	N/A	$0.56 per share	1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	-508.70%	N/A
CLYM Climb Bio	-$73.90M	-$2.38	N/A	N/A	N/A	N/A	-43.95%	-42.94%	8/13/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-326.95%	-181.34%	8/6/2025 (Estimated)
IVVD Invivyd	-$169.93M	-$1.20	N/A	6.66	N/A	-389.01%	-165.24%	-99.71%	8/13/2025 (Estimated)

Latest ASBP, IMUX, CLYM, and IVVD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2025	IMUX Immunic	-$0.19	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	CLYM Climb Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	IVVD Invivyd	-$0.04	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	0.22	0.22
CLYM Climb Bio	N/A	14.25	14.25
IMUX Immunic	N/A	0.74	0.74
IVVD Invivyd	N/A	1.53	1.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
CLYM Climb Bio	69.76%
IMUX Immunic	51.82%
IVVD Invivyd	70.36%

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	48.00%
CLYM Climb Bio	0.80%
IMUX Immunic	4.60%
IVVD Invivyd	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	49.53 million	25.75 million	N/A
CLYM Climb Bio	9	67.58 million	67.04 million	N/A
IMUX Immunic	70	95.82 million	91.41 million	Optionable
IVVD Invivyd	100	119.96 million	89.49 million	Optionable

ASBP, IMUX, CLYM, and IVVD Headlines

Recent News About These Companies

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for ...

July 23, 2025 | bakersfield.comB

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

July 23, 2025 | globenewswire.com

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

July 21, 2025 | globenewswire.com

Invivyd (NASDAQ:IVVD) Trading Up 5.1% - Here's Why

July 18, 2025 | marketbeat.com

Invivyd, Inc. (IVVD) stock price, news, quote & history - Yahoo Finance

July 8, 2025 | nz.finance.yahoo.com

Invivyd, Inc. Forms SPEAR Study Group to Investigate PEMGARDA® Therapy for Long COVID and Post-Vaccination Syndrome

July 2, 2025 | quiverquant.comQ

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

July 2, 2025 | globenewswire.com

Invivyd, Inc. Announces Promising Phase 1/2 Data for VYD2311 Monoclonal Antibody Candidate in COVID-19 Prevention and Treatment

June 26, 2025 | quiverquant.comQ

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

June 26, 2025 | globenewswire.com

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

May 29, 2025 | msn.com

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025 | globenewswire.com

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network®

May 23, 2025 | bakersfield.comB

Invivyd, Inc. Announces Inclusion of PEMGARDA® in NCCN Clinical Practice Guidelines for B-Cell Lymphomas

May 23, 2025 | quiverquant.comQ

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025 | globenewswire.com

Invivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster Efficacy

May 23, 2025 | nasdaq.com

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025 | globenewswire.com

Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss

May 16, 2025 | investing.com

Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...

May 16, 2025 | finance.yahoo.com

Invivyd Reports Q1 2025 Financial Results and Outlook

May 15, 2025 | tipranks.com

INVIVYD Earnings Preview: Recent $IVVD Insider Trading, Hedge Fund Activity, and More

May 15, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP, IMUX, CLYM, and IVVD Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$0.36 -0.02 (-5.43%)

As of 08/1/2025 03:59 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Climb Bio NASDAQ:CLYM

$1.45 +0.05 (+3.57%)

As of 08/1/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Immunic NASDAQ:IMUX

$0.93 -0.01 (-0.91%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.94 +0.01 (+0.81%)

As of 08/1/2025 07:23 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Invivyd NASDAQ:IVVD

$0.73 +0.04 (+5.52%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.74 +0.00 (+0.51%)

As of 08/1/2025 07:32 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time